Objective: Angiotensin-converting enzyme (ACE) gene produces an ACE protein which is the key component of the renin-angiotensin system and contains several polymorphisms which affects the physical performance that is significantly important for athletes. Insertion/deletion (I/D) and G2350A polymorphisms which have one of the most powerful influences in the ACE gene is known to regulate cardiovascular mechanisms by taking a role in angiotensin-system.
Methods:The present study aimed to investigate the genetic association and haplotypes formed by rs1799752 (ACE I/D) and rs4343 (ACE G2350A) polymorphisms in essential hypertension patients, elite athletes and healthy controls in total 79 subjects (27 hypertension patients, 27 elite athletes and 25 control group individuals) from Turkish population. In this study, ACE I/D and G2350A polymorphisms were genotyped by using polymerase chain reaction and restriction fragment length polymorphism (PCR-RFLP) method and identified by bioanalyzer after restriction digestion.
Results:The prevalence of genotype frequencies of the ACE rs1799752 II/ID/DD was 3.7%, 44.44%, 51.85% in hypertension patients; 3.7%, 33.33%, 62.96% in elite athletes and 12%, 24%, 64% in healthy controls, respectively. Also, the prevalence of genotype frequencies of the ACE rs4343 GG/GA/AA was 7.41%, 77.78%, 14.81% in hypertension patients; 0%, 77.78%, 22.22% in elite athletes and 4%, 84%, 12% in healthy controls, respectively.
Conclusion:Our data suggest that "D" allele for I/D and "A" allele for G2350A polymorphisms of ACE gene may have a potential role with a large number of patients and control groups in Turkish population.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.